The unique combination in this medication supports symptomatic relief across key domains when acute illness involves several distressing symptoms concurrently. It is applied in situations where symptoms create noticeable interference with daily stability and requires supportive management. The core component is considered relevant for the management of severe pain and high fever that is unresponsive to other treatments.

The medication is relevant for managing symptom clusters that may become intense or disruptive, such as moderate to severe pain, high fever, and discomfort linked to smooth muscle spasms. This includes conditions presenting with systemic discomfort such as flu-like illnesses, or localized intense pain, like renal or biliary colic, as well as musculoskeletal pain syndromes, including neuralgia and myositis. The combination supports management of the overall symptom burden, which contributes to day-to-day comfort during periods of heightened symptoms.

“This medication is commonly used when symptoms cluster into patterns requiring supportive management, providing assistance during periods of heightened discomfort.”

Quick Summary of Therapeutic Focus
Primary Symptoms Managed	High Fever, Moderate to Severe Pain, Muscular Spasm/Tension
Relevant Conditions	Acute febrile states, Colic (renal/biliary), Neuralgia, Myositis
General Benefit	Assists with maintaining functional stability by easing the overall symptom burden

Regulatory References

1. Netherlands Medicines Evaluation Board

Eligibility Map: Who can and cannot use Анальгин-хинин

Official regulatory information defines strict population eligibility for Анальгин-хинин (Sodium Metamizole/Quinine) based on documented contraindications and restrictions.

---

Contraindicated Populations

Use is absolutely prohibited for patients with a known history of Hypersensitivity to Metamizole or Quinine, or those with underlying blood disorders, including Impaired Haematopoiesis (e.g., bone marrow suppression) and Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency. The medicine is also contraindicated in cases of Acute Hepatic Porphyria, severe cardiac conduction defects (like QT prolongation), and in patients with Optic Neuritis or Myasthenia Gravis.

---

Age and Physiological Restrictions

Age: The drug is contraindicated in infants below 3 months or 5 kg body weight. Use is not recommended for children and adolescents under 15 years of age. Older adults require cautious use.

Pregnancy/Lactation: Use is strictly contraindicated during the Third Trimester of Pregnancy and advised against during the first two trimesters and Lactation.

Organ Function: Patients with severe chronic renal or hepatic impairment are restricted from use or require significant caution, based on official labeling.

Interactions with other medicines and products

The interaction profile of Анальгин-хинин is defined by the distinct pharmacokinetic and pharmacodynamic properties of its two active components, Sodium Metamizole and Quinine, as documented in official regulatory labeling.

Contraindicated Combinations

Co-administration is formally contraindicated with certain agents due to severe interaction risks. These include other antimalarials like Mefloquine, Class IA and Class III antiarrhythmic agents (e.g., Amiodarone), and certain antipsychotics, as these significantly increase the risk of ventricular arrhythmias caused by Quinine. The combination with Methotrexate is also prohibited, as Metamizole increases the plasma concentration of Methotrexate, risking toxicity.

Pharmacokinetic and Timing Constraints

Metamizole acts as an enzyme inducer, causing a documented reduction in the plasma concentrations of co-administered medicines, including Cyclosporine, Bupropion, and Efavirenz. Conversely, Quinine is a P-glycoprotein (P-gp) inhibitor, which results in an expected increase in the plasma concentration of P-gp substrates, such as Digoxin. A specific timing-separation rule is required for Low-Dose Aspirin; Metamizole must be administered at least 30 minutes before or 8 hours after Aspirin to prevent interference with its antiplatelet effect.

Food, Alcohol, and Population Notes

The effects of Alcohol are officially noted to be potentiated by Metamizole. The regulatory labeling also specifies that reduced clearance in patients with severe hepatic impairment (Child-Pugh C) increases the risk of pharmacodynamic interactions with Quinine.

Анальгин-хинин functions through the pharmacodynamic actions of its two components: Metamizole and Quinine.

Metamizole, a prodrug, is rapidly converted into the active metabolites 4-methyl-amino-antipyrine (MAA) and 4-amino-antipyrine (AA). Its action involves the central nervous system (CNS) where MAA and AA serve as non-selective cyclooxygenase (COX) enzyme inhibitors, with a potential selectivity for the putative COX-3 isoform in the brain and spinal cord. This inhibition decreases the synthesis of specific prostaglandins, lipid mediators involved in central thermoregulation and nociception. Downstream cascades also include the activation of the endogenous opioidergic and cannabinoid systems in the CNS, contributing to altered pain signaling. The molecule also exhibits a peripheral spasmolytic effect via a mechanism associated with reduced inositol phosphate synthesis, which modulates intracellular calcium release in smooth muscle tissue.

Quinine acts primarily by accumulating in the acidic food vacuole of susceptible blood-stage parasites. As a weak base, it interferes with the parasite's detoxification of hemoglobin breakdown products. Quinine is a proposed inhibitor of the parasite's heme polymerase enzyme, preventing the biomineralization of cytotoxic heme into the inert, crystalline pigment hemozoin. The resultant buildup of free heme and its derivatives leads to oxidative stress and cellular disruption within the parasite.

System-level physiological consequences of the combined action include central modulation of thermoregulatory centers and peripheral smooth muscle relaxation, alongside the antiparasitic disruption of heme metabolism.

How to use Анальгин-хинин

This section outlines the general principles and administration rules for the fixed-dose combination of Sodium Metamizole and Quinine.

Administration and Dosing Principles

The primary route of administration for this combination is oral, as the drug is provided in a tablet form. General administration principles involve using the lowest single dose necessary to control symptoms. Dosing is adjusted based on the required effect, not exceeding established limits.

For adults and adolescents 15 years of age or older (weighing over 53 kg), the single dose of the Metamizole component ranges from 500 mg up to 1,000 mg. A single dose may be taken up to four times daily, provided that an interval of 6 to 8 hours is maintained between administrations. The maximum daily intake of the Metamizole component is limited to 4,000 mg. The onset of effect after oral administration is typically expected within 30 to 60 minutes.

Contextual Usage and Population Rules

Taking the dose with food can be done to minimize potential gastric discomfort. This combination product is intended for short-term use only.

The tablet strength is generally not recommended for use in children younger than 10 years of age. For adolescents aged 15 years and older who meet the minimum weight criteria, the adult dosing regimen is applicable. Dosage adjustments are typically required for older or debilitated patients due to changes in drug elimination.

Analgin-Quinine: Research Evidence Overview

This section provides a descriptive overview of the types of clinical studies that have investigated agents containing Metamizole (Analgin) and Quinine.

---

Metamizole Research

Research on Metamizole has primarily explored its use in treating acute severe pain and fever that is unresponsive to other common treatments. Studies have examined the effect of Metamizole across various clinical settings, including post-operative pain and pain associated with colic. A significant body of research exists concerning its dose-response relationship and comparison with other non-opioid analgesics.

• Analgesic Effect: Clinical research has investigated outcomes related to pain reduction, particularly for visceral and somatic pain. Evidence suggests a rapid onset of pain-relieving action, making the agent a subject of investigation for acute pain management.
• Antipyretic Effect: Studies have also explored its effect in reducing high fever, especially in cases where conventional antipyretics are contraindicated or ineffective.

---

Quinine Research

Quinine, the second component, is primarily studied for the treatment of chloroquine-resistant P. falciparum malaria. Its use is well-established in this context, and clinical trials focus on optimal dosing regimens and combinations to improve therapeutic efficacy and reduce resistance.

While Quinine has been historically used to explore its potential in treating nocturnal leg cramps, systematic reviews and regulatory evaluations have concluded that the evidence supporting this use is generally limited or conflicting. As such, Quinine's role in contemporary clinical evidence is overwhelmingly focused on antimalarial therapy.

---

Combination Research

Research investigating the specific combination of Metamizole and Quinine is less common than studies on the individual components. The rationale for combination therapy usually centers on utilizing Quinine's muscle relaxant properties alongside Metamizole's analgesic effect to potentially address pain associated with muscle spasms or tension. However, the outcomes regarding whether this specific combination provides added clinical benefit over the individual components for standard indications require further evidence.

Common questions about Анальгин-хинин (FAQ)

---

Q: How long does the effect of Analgin-Quinine typically last?

The official product information indicates that the onset of the pain-relieving action of the Metamizole component is expected within 30 to 60 minutes after taking the tablet. The duration of this effect is usually described in regulatory documents as lasting for 4 to 6 hours.

---

Q: What common side effects are mentioned for Analgin-Quinine?

According to the official safety profile, common anticipated effects are often related to Cinchonism from the Quinine component, which includes symptoms like headache, vertigo (dizziness), tinnitus (ringing in the ears), and blurred vision. Other frequently reported effects include general issues like nausea, vomiting, drowsiness, and skin rash.

---

Q: What happens if Analgin-Quinine is taken with other pain relievers?

Regulatory information highlights specific interaction risks, such as the potential for interference with the antiplatelet effect of Low-Dose Aspirin, which requires a strict timing-separation rule. Official documents emphasize the importance of informing a healthcare professional about all other pain relievers being taken to manage potential risks.

---

Q: Why is it important not to exceed the recommended frequency of Analgin-Quinine?

Official regulatory guidelines establish strict limits on the maximum daily dose and frequency of administration. This is necessary because exceeding these limits can increase the risk of dose-dependent adverse reactions, including severe drops in blood pressure (hypotension) and other systemic toxicities.

---

Q: What is the official age limit for the use of Analgin-Quinine?

According to official eligibility criteria, this medicine is strictly contraindicated for infants under 3 months or 5 kg body weight. Use is generally not recommended for children and adolescents under 15 years of age, though the adult dosing regimen may apply to adolescents 15 years and older who meet a minimum weight criterion.

---

Q: Does Analgin-Quinine affect the ability to drive or operate machinery?

Official warnings state that the medicine may cause side effects such as dizziness, drowsiness, or visual disturbances (blurred vision). If these effects occur, activities requiring concentration, such as driving or operating machinery, are generally advised against in official warnings.

---

Q: What is agranulocytosis and how is it related to Analgin-Quinine?

Agranulocytosis is a rare but severe disorder of the blood system where the body's production of white blood cells is critically decreased. Official warnings note that this condition is a potential risk associated with the drug. Official instructions indicate that if symptoms suggesting agranulocytosis develop (e.g., fever, sore throat), the medicine should be discontinued and medical help should be sought immediately.

---

Q: Are interactions with herbal supplements described for Analgin-Quinine?

While specific details about every herbal product may not be listed, regulatory guidelines emphasize that patients should inform a healthcare provider about all current medications, including any herbal products and nutritional supplements. This precaution is highlighted due to the potential for unlisted interaction risks with the active components.

---

Q: What is known about Analgin-Quinine overdose?

The official product information includes a specific section detailing the risks and management of an overdose. Symptoms associated with an overdose of the Metamizole component may include nausea, severe stomach pain, kidney damage, convulsions, and a critical drop in blood pressure (hypotension).

---

Q: What is the main difference between Analgin-Quinine and pure Analgin?

The primary difference between the two preparations is the addition of Quinine. The combination is formulated to provide three key actions: analgesia, antipyresis, and the specialized action of skeletal muscle relaxation, which is the property contributed by Quinine.

---

Q: Can Analgin-Quinine help with flu or cold symptoms?

The general purpose of the medicine is indicated for the relief of pain, fever, and generalized body aches associated with common seasonal illnesses. Official therapeutic indications cover the management of acute moderate to severe pain and high fever that is unresponsive to other treatments.

---

Q: Is there information that Analgin-Quinine causes drowsiness?

Yes, according to the official safety profile, both drowsiness (sleepiness) and dizziness are described as potential common side effects that may occur during the course of treatment.

---

Q: Is it true that components of Analgin-Quinine are banned in some countries?

Official regulatory documents confirm that the active component Metamizole (Analgin) has a varying global status and is restricted or banned in certain countries, including the United States, Japan, and Australia. This restriction is primarily due to the rare but serious risk associated with agranulocytosis, a blood disorder.

---

Q: What should I do if a dose of Analgin-Quinine is missed?

The official administration instructions, usually found in the Patient Information Leaflet or SmPC, include specific guidance detailing how to proceed if a planned dose is missed. It is important that this official guidance be reviewed.

---

Q: What research has been conducted on the efficacy of Analgin-Quinine?

Official regulatory information indicates that research focused specifically on the fixed combination of Metamizole and Quinine is less common than studies on the individual components. The rationale for combining them generally centers on utilizing Quinine’s property as a skeletal muscle relaxant alongside Metamizole's established pain relief action.

---

Q: Why is Quinine added to Analgin in this preparation?

Quinine is included in the preparation to provide a distinct pharmacological action: skeletal muscle relaxation. This action is intended to complement and enhance the analgesic (pain relief) and antipyretic (fever reduction) properties already provided by Metamizole (Analgin).

---

Q: Is Analgin-Quinine an anti-inflammatory drug?

The medicine is formally classified in regulatory documents as a Combined Analgesic and Antipyretic Agent. While the Metamizole component acts through pathways that inhibit prostaglandins, it is noted to have only a minor anti-inflammatory effect at the therapeutic doses commonly administered.

---

Q: Can Analgin-Quinine affect blood test results?

Yes, the medicine is associated with a risk of serious blood disorders, such as agranulocytosis and thrombocytopenia. Regulatory information indicates that the drug may also potentially cause temporary changes in routine blood cell levels, including platelets and white blood cells.

---

Q: What are the signs of an allergic reaction to Analgin-Quinine?

The official safety profile notes the potential for severe reactions, including anaphylactic shock, which is a severe event documented in the official safety profile. Signs of a less severe hypersensitivity reaction can include skin changes like a rash, itching, hives, or swelling of the face, lips, or tongue.

---

Q: Are there restrictions on the duration of treatment with Analgin-Quinine?

Yes, regulatory documents explicitly specify that this medicine is intended for short-term use only. This duration restriction applies to the management of acute pain and fever.

---

Q: How is Analgin-Quinine described in the official instructions?

In official instructions, this medicine is described as a Fixed-Dose Combination Drug. It is formally classified as a Combined Analgesic and Antipyretic Agent due to the complementary effects of its two active ingredients.

---

Q: In what cases do doctors most often prescribe Analgin-Quinine?

Official therapeutic indications cover the management of high fever that is unresponsive to other treatments, as well as acute moderate to intense pain. This includes pain from various origins, such as post-operative or post-traumatic pain, and pain associated with muscle tension.

---

Q: What is a 'fixed combination' in the context of Analgin-Quinine?

A Fixed-Dose Combination Drug is a single tablet or formulation that contains two or more different active ingredients, such as Metamizole and Quinine, combined in predetermined, non-adjustable amounts. This strategy is recognized in guidelines for optimizing the management of concurrent symptoms.

---

Q: Why might Quinine be important for certain infections?

The component Quinine is recognized in official guidelines for its established use as an antimalarial agent. Its use is focused on the treatment of specific, severe parasitic infections, particularly chloroquine-resistant P. falciparum malaria.

---

Q: What precautions are described in the official instructions for Analgin-Quinine?

Official documentation outlines specific precautions, including the need for careful use in older adults and patients with known reduced kidney or liver function. Furthermore, the instructions advise heightened vigilance for symptoms of blood disorders, such as agranulocytosis, throughout the duration of treatment.

---

Q: Does taking food affect the action of Analgin-Quinine?

Official guidance regarding the Quinine component suggests that taking the medication with food may help minimize the risk of potential gastric upset.

---

Q: Can Analgin-Quinine affect blood pressure?

Yes, the official safety profile notes that the Metamizole component can cause severe hypotensive reactions, which is a critical and potentially dose-dependent drop in systolic blood pressure. This effect is a documented risk, especially when higher doses are used.

Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing Анальгин-хинин (Sodium Metamizole/Quinine) to maintain product stability. The medication must be kept at controlled room temperature, typically between 20 C and 25 C. Storage environments must protect the product from excess heat and moisture; therefore, refrigeration, freezing, and storage in the bathroom are strictly prohibited.

Storage Restriction	Requirement
Temperature	Controlled Room Temperature (20 C to 25 C)
Container	Keep in original container, tightly closed
Prohibited	Do not refrigerate or freeze
Safety	Keep out of the sight and reach of children

Disposal of unused or expired product should follow official guidance, such as utilizing a drug take-back program or a mail-back service. If these options are unavailable, the medication must be mixed with an unappealing substance, placed in a sealed bag, and discarded in the household trash, without crushing the tablets.